Scientists have revealed that a new research could be a new hope for treating liver transplant patients with recurring hepatitis C (HCV).
The scientists gave sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) to post-liver transplant patients with recurring HCV, who had exhausted all treatment options and had poor clinical prognoses, for up to 48 weeks.
According to the study, 62 percent of the patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests.
Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy, said that there are no effective treatment options for this patient group, but their new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.
Burra added that this could be a second chance for patients with advanced hepatitis C liver disease, liver transplants and for those who continue to suffer post-surgery, it's important for us to keep following up all avenues possible to improve their quality of life.